Obermatt
See Similar Stocks →

Flags

Financial distress

BioCryst Pharmaceuticals

NSQ:BCRX · US09058V1035
BiotechnologyMedium

360

52
EV / EBIT46
Price / Owner Earnings28
Owner Earnings Yield1
Dividend Yield1
Price/Sales68
EV / Gross Profit95
Price/Book80
Return on Capital100
Cash Return on Capital1
EBIT Margin85
Gross Profitability100
Accruals100
Owner Earnings Margin60
Sales growth21
Profit Growth85
Long-Term EPS Growth39
Reinvestment29
Price momentum14
Debt load3
Refinancing50
Debt Payback1
Liquidity77
Analyst ratings53
Opinion Changes50
Price Target Upside96
Market mood63
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

BioCryst Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded1991
Employees550
Websitebiocryst.com
ISINUS09058V1035
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyDermatologyOphthalmologyInfectious DiseasesAllergyBiotechnologyClinical TrialsTherapeutics

Description

BioCryst Pharmaceuticals, Inc. (BioCryst) operates as a global biotechnology company. The company focuses on developing and commercializing medicines for hereditary angioedema (‘HAE’) and other rare diseases, driven by the company’s deep commitment…

Analysis

Quality compounder

BioCryst Pharmaceuticals, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
13
2026

All-time high

34

Mar 2026

All-time low

13

Jun 2026

Average rank

24

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
68
—
—
—
Price/Earnings
12
—
—
—
Price/Book
80
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
38
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare BioCryst Pharmaceuticals with its peers
Rezolute
NAQ:RZLT
53
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Catalyst Pharmaceuticals
NAQ:CPRX
96
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Kalvista Pharmaceuticals
NMQ:KALV
60
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vera Therapeutics
NMQ:VERA
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Ironwood Pharmaceuticals
NSQ:IRWD
92
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Erasca
NSQ:ERAS
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →